India, June 26 -- Pfizer Inc. (PFE) Thursday reported positive topline results from the Phase 3 BASIS study of Hympavzi for adults and adolescents living with hemophilia A or B with inhibitors. The study met its primary goal.
The primary endpoint of the study measured the treated annualized bleeding rate (ABR) during the 12-month active treatment period with Hympavzi compared to treated ABR on prior on-demand replacement therapy in participants aged between 12 and 75 with hemophilia A or hemophilia B with inhibitors. Hympavzi was superior to on-demand treatment with a 93% reduction in ABR over 12 months. Further, the drug was well tolerated, consistent with the non-inhibitor cohort of the BASIS study and Phase 1/2 results.
googletag.cmd.p...